MARKET

CLRB

CLRB

Cellectar Biosciences Inc
NASDAQ
1.793
-0.009
-0.48%
Opening 13:51 06/08 EDT
OPEN
1.800
PREV CLOSE
1.802
HIGH
1.840
LOW
1.770
VOLUME
16.81K
TURNOVER
25.17K
52 WEEK HIGH
6.76
52 WEEK LOW
1.250
MARKET CAP
17.47M
P/E (TTM)
-0.4499
1D
5D
1M
3M
1Y
5Y
Maxim Group Keeps Their Buy Rating on Cellectar Biosciences (CLRB)
TipRanks · 05/05 18:45
Cellectar Biosciences GAAP EPS of -$0.76
Seeking Alpha · 05/04 14:10
Recap: Cellectar Biosciences Q1 Earnings
Benzinga · 05/04 13:45
BRIEF-Cellectar Reports Financial Results For First Quarter 2023 And Provides A Corporate Update
Reuters · 05/04 12:42
Cellectar Biosciences Q1 EPS $(0.76) Beats $(1.00) Estimate
Benzinga · 05/04 12:41
MaxCyte Appoints Douglas Swirsky As Chief Financial Officer
Benzinga · 03/27 20:16
Cellectar Biosciences (CLRB) Investor Presentation - Slideshow
Seeking Alpha · 03/17 18:43
Cellectar Biosciences GAAP EPS of -$4.05 misses by $0.74
Seeking Alpha · 03/09 13:59
More
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on to develop PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. It is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase 1 CLOVER-2 study.

Webull offers kinds of Cellectar Biosciences Inc stock information, including NASDAQ:CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.